Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | lysine (K)-specific methyltransferase 2A | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma japonicum | ko:K09188 myeloid/lymphoid or mixed-lineage leukemia protein 3, putative | Get druggable targets OG5_130642 | All targets in OG5_130642 |
Neospora caninum | Multidomain chromatinic protein with the following architecture: 3x PHD-bromo-3xPHD-SET domain and associated cysteine cluster a | Get druggable targets OG5_130642 | All targets in OG5_130642 |
Toxoplasma gondii | histone lysine methyltransferase SET1 | Get druggable targets OG5_130642 | All targets in OG5_130642 |
Schistosoma mansoni | mixed-lineage leukemia protein mll | Get druggable targets OG5_130642 | All targets in OG5_130642 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.3713 | 0.5 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.042 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.042 | 0.5 |
Loa Loa (eye worm) | CXXC zinc finger family protein | 0.0035 | 0.4331 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.3713 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.3713 | 0.5 |
Echinococcus multilocularis | cpg binding protein | 0.0037 | 0.4619 | 1 |
Trichomonas vaginalis | helicase, putative | 0.0008 | 0.042 | 0.5 |
Brugia malayi | CXXC zinc finger family protein | 0.0035 | 0.4331 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.3713 | 0.5 |
Echinococcus granulosus | cpg binding protein | 0.0037 | 0.4619 | 1 |
Schistosoma mansoni | mixed-lineage leukemia protein mll | 0.0009 | 0.0531 | 0.0531 |
Echinococcus multilocularis | histone lysine N methyltransferase MLL3 | 0.0011 | 0.0839 | 0.0754 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.042 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.042 | 0.5 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.042 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.3713 | 0.8229 |
Schistosoma mansoni | hypothetical protein | 0.0014 | 0.1265 | 0.1265 |
Onchocerca volvulus | 0.0035 | 0.4331 | 0.5 | |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.042 | 0.5 |
Toxoplasma gondii | histone lysine methyltransferase SET1 | 0.0066 | 0.8854 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.042 | 0.5 |
Schistosoma mansoni | cpg binding protein | 0.0037 | 0.4619 | 0.4619 |
Schistosoma mansoni | cpg binding protein | 0.0035 | 0.4331 | 0.4331 |
Brugia malayi | hypothetical protein | 0.002 | 0.214 | 0.376 |
Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0008 | 0.042 | 0.5 |
Echinococcus granulosus | Ataxin 2 N terminaldomain containing protein | 0.0014 | 0.1265 | 0.1796 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.042 | 0.5 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.042 | 0.5 |
Brugia malayi | hypothetical protein | 0.003 | 0.3713 | 0.8239 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.3713 | 0.5 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.042 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.042 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.042 | 0.5 |
Schistosoma mansoni | cpg binding protein | 0.0037 | 0.4619 | 0.4619 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.3713 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.042 | 0.5 |
Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0008 | 0.042 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.042 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.3713 | 0.5 |
Echinococcus granulosus | histone lysine N methyltransferase MLL3 | 0.0011 | 0.0839 | 0.0754 |
Echinococcus multilocularis | Ataxin 2, N terminal,domain containing protein | 0.0014 | 0.1265 | 0.1796 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.042 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.3548 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 14.1254 um | PUBCHEM_BIOASSAY: qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction. (Class of assay: confirmatory) [Related pubchem assays: 2698 (Summary assay.)] | ChEMBL. | No reference |
Potency (functional) | 14.7157 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.